AU2003299489B2 - Interacting site for gp41 on gp120 of HIV-1 - Google Patents

Interacting site for gp41 on gp120 of HIV-1 Download PDF

Info

Publication number
AU2003299489B2
AU2003299489B2 AU2003299489A AU2003299489A AU2003299489B2 AU 2003299489 B2 AU2003299489 B2 AU 2003299489B2 AU 2003299489 A AU2003299489 A AU 2003299489A AU 2003299489 A AU2003299489 A AU 2003299489A AU 2003299489 B2 AU2003299489 B2 AU 2003299489B2
Authority
AU
Australia
Prior art keywords
chimera
neutralization
hiv
gpl20
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2003299489A
Other languages
English (en)
Other versions
AU2003299489A1 (en
Inventor
Gerald V. Quinnan Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Original Assignee
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry M Jackson Foundation for Advancedment of Military Medicine Inc filed Critical Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Publication of AU2003299489A1 publication Critical patent/AU2003299489A1/en
Application granted granted Critical
Publication of AU2003299489B2 publication Critical patent/AU2003299489B2/en
Assigned to THE HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC reassignment THE HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC Alteration of Name(s) of Applicant(s) under S113 Assignors: The Henry M Jackson Foundation
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003299489A 2002-05-10 2003-05-12 Interacting site for gp41 on gp120 of HIV-1 Expired - Fee Related AU2003299489B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37905202P 2002-05-10 2002-05-10
US60/379,052 2002-05-10
PCT/US2003/014721 WO2004045495A2 (en) 2002-05-10 2003-05-12 Interacting site for gp41 on gp120 of hiv-1

Publications (2)

Publication Number Publication Date
AU2003299489A1 AU2003299489A1 (en) 2004-06-15
AU2003299489B2 true AU2003299489B2 (en) 2009-01-15

Family

ID=32326162

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003299489A Expired - Fee Related AU2003299489B2 (en) 2002-05-10 2003-05-12 Interacting site for gp41 on gp120 of HIV-1

Country Status (6)

Country Link
US (1) US20080057492A1 (https=)
EP (1) EP1553978A4 (https=)
JP (1) JP2006504435A (https=)
AU (1) AU2003299489B2 (https=)
CA (1) CA2483870A1 (https=)
WO (1) WO2004045495A2 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858366A (en) * 1990-05-16 1999-01-12 Dana-Farber Cancer Institute Immunogenic peptides, antibodies and uses thereof relating to CD4 receptor binding

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683136A (en) * 1985-03-06 1987-07-28 Scripps Clinic And Research Foundation Proteinaceous antigens with conformation-independent and conformation-dependent determinants
ES2115622T5 (es) * 1990-10-17 2003-03-16 Us Health Clones moleculares de hiv-1 y usos de los mismos.
US5696238A (en) * 1991-08-20 1997-12-09 Chiron Corporation Purified GP120 composition retaining natural conformation
US5505947A (en) * 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
ATE435034T1 (de) * 1998-08-04 2009-07-15 Jackson H M Found Military Med Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisierenden antikörperantwort assoziiert ist.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858366A (en) * 1990-05-16 1999-01-12 Dana-Farber Cancer Institute Immunogenic peptides, antibodies and uses thereof relating to CD4 receptor binding

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Park, E & Quinnan, J. R. Journal of Virology, July 1999, pages 5707-5713. *
Park, E. et al. Journal of Virology May 2000, pages 4183-4191. *
Park, E. et al. Journal of Virology September 1998, pages 7099-7107. *

Also Published As

Publication number Publication date
WO2004045495A3 (en) 2005-05-19
EP1553978A2 (en) 2005-07-20
JP2006504435A (ja) 2006-02-09
AU2003299489A1 (en) 2004-06-15
US20080057492A1 (en) 2008-03-06
EP1553978A4 (en) 2008-02-20
WO2004045495A2 (en) 2004-06-03
CA2483870A1 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
AU700371B2 (en) Hiv envelope polypeptides
Song et al. Molecularly cloned SHIV-1157ipd3N4: a highly replication-competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env
AP1282A (en) HIV envelope polypeptides and vaccine.
Berman et al. Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand
Kayman et al. Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains
Srivastava et al. Role of neutralizing antibodies in protective immunity against HIV
Cole et al. Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain
Montefiori et al. Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies
Fox et al. Length polymorphism within the second variable region of the human immunodeficiency virus type 1 envelope glycoprotein affects accessibility of the receptor binding site
AU762376C (en) Expression and characterization of HIV-1 envelope protein associated with a broadly reactive neutralizing antibody response
Rasmussen et al. Efficacy of a multigenic protein vaccine containing multimeric HIV gp160 against heterologous SHIV clade C challenges
US20100080818A1 (en) Expression and Characterization of HIV-1 Envelope Protein Associated with Broadly Cross Reactive Neutralizing Antibody Response
JP5290576B2 (ja) 修飾されたｈｉｖ−１エンベロープタンパク質
AU2003299489B2 (en) Interacting site for gp41 on gp120 of HIV-1
WO2003062377A2 (en) COMPLETE GENOME SEQUENCE OF SIVcpzTAN1
Protection Vaccination of Rhesus Macaques with

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee